Fertility Protection in Female Oncology Patients: How Should Patients Be Counseled?

被引:18
作者
Findeklee, S. [1 ]
Lotz, L. [1 ]
Heusinger, K. [1 ]
Hoffmann, I. [2 ]
Dittrich, R. [2 ]
Beckmann, M. W. [1 ]
机构
[1] Univ Klinikum Erlangen, Gynecol & Obstet, D-91012 Erlangen, Germany
[2] Univ Klinikum Erlangen, Gynecol Endocrinol & Reprod Med, D-91012 Erlangen, Germany
关键词
fertility preservation; cancer; wish for a child; CRYOPRESERVED OVARIAN TISSUE; BREAST-CANCER PATIENTS; OOCYTE CRYOPRESERVATION; RADICAL TRACHELECTOMY; HODGKINS-LYMPHOMA; AMERICAN-SOCIETY; ADJUVANT THERAPY; YOUNG-WOMEN; PRESERVATION; TRANSPLANTATION;
D O I
10.1055/s-0035-1558184
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Protecting the fertility of patients with oncologic disease is becoming more and more important, as fulfilling the wish to have children is increasingly occurring at a later stage in life and long-term survival rates after cancer are continuing to improve. A number of fertility-preserving options exist. In addition to techniques which have been around for some time such as medical ovarian suppression, ovarian transposition, and organ-preserving surgery, there are other, more recent, innovative methods which have developed over the last few years such as cryopreservation of oocytes or ovarian tissue transplantation after completing cancer therapy. As every procedure has its specific advantages and disadvantages, informed patient consent is essential. The physician's aim must be to select the optimal procedure for each patient. The extent of patients' information about the options to preserve fertility in women with oncologic disease remains limited. One of the main reasons for this is that clinicians are not sure how to inform patients about existing procedures and methods. The aim of this review article is to provide help in clinical practice.
引用
收藏
页码:1243 / 1249
页数:7
相关论文
共 57 条
[1]   The Effects of Paclitaxel, Dose Density, and Trastuzumab on Treatment-Related Amenorrhea in Premenopausal Women With Breast Cancer [J].
Abusief, Mary E. ;
Missmer, Stacey A. ;
Ginsburg, Elizabeth S. ;
Weeks, Jane C. ;
Partridge, Ann H. .
CANCER, 2010, 116 (04) :791-798
[2]   Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens [J].
Alejandro Perez-Fidalgo, Jose ;
Rosello, Susana ;
Garcia-Garre, Elisa ;
Jorda, Esther ;
Martin-Martorell, Paloma ;
Bermejo, Begona ;
Chirivella, Isabel ;
Guzman, Cecilia ;
Lluch, Ana .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 120 (01) :245-251
[3]   Fertility sparing treatment in borderline ovarian tumours [J].
Alvarez, Rosa Maria ;
Vazquez-Vicente, Daniel .
ECANCERMEDICALSCIENCE, 2015, 9
[4]   Ovarian cryopreservation for fertility preservation: indications and outcomes [J].
Anderson, R. A. ;
Wallace, W. H. B. ;
Baird, D. T. .
REPRODUCTION, 2008, 136 (06) :681-689
[5]   Ovarian function 6 years after cryopreservation and transplantation of whole sheep ovaries [J].
Arav, A. ;
Gavish, Z. ;
Elami, A. ;
Natan, Y. ;
Revel, A. ;
Silber, S. ;
Gosden, R. G. ;
Patrizio, P. .
REPRODUCTIVE BIOMEDICINE ONLINE, 2010, 20 (01) :48-52
[6]   GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data [J].
Beck-Fruchter, R. ;
Weiss, A. ;
Shalev, E. .
HUMAN REPRODUCTION UPDATE, 2008, 14 (06) :553-561
[7]   Doxorubicin-induced ovarian toxicity [J].
Ben-Aharon, Irit ;
Bar-Joseph, Hadas ;
Tzarfaty, Galia ;
Kuchinsky, Lital ;
Rizel, Shulamith ;
Stemmer, Salomon M. ;
Shalgi, Ruth .
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, 2010, 8
[8]  
Bevacizumab Genentech Inc., 2011, [No title captured], Patent No. [U. S. BL125085, 125085]
[9]   GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy [J].
Blumenfeld, Zeev ;
von Wolff, Michael .
HUMAN REPRODUCTION UPDATE, 2008, 14 (06) :543-552
[10]  
Carcio Helen Nelson, 1998, MANAGEMENT INFERTILE